C86.41
Blastic NK-cell lymphoma, in remission
Clinical Classification Guidelines
Inclusion Terms
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN), in remission
Medical Intelligence & Overview
Blastic NK-cell lymphoma, in remission, is a type of blood cancer that has responded well to treatment, leading to a period where signs and symptoms temporarily decrease or disappear. This condition involves cancerous cells originating from natural killer (NK) cells, which are a part of the immune system that helps fight infections and illnesses. When in remission, it indicates that the disease is not currently active, although it may require ongoing monitoring and care.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting NK cells Environmental exposures that could influence cell mutations Previous exposure to radiation or certain chemotherapy drugs Unknown factors, as the precise cause of most lymphomas is not well understood
Key Symptoms: Persistent fatigue or weakness Swollen lymph nodes, often painless Unexplained weight loss Fever or night sweats Frequent infections due to immune suppression Unusual bleeding or bruising Abdominal discomfort or pain
Diagnostic & Treatment
Diagnosis Path: Diagnosis of blastic NK-cell lymphoma in remission involves multiple steps:
Treatment Protocols: While remission indicates that active treatment may not be necessary, ongoing management could include:
Clinical Advice & FAQs
Billing Guidance
Is C86.41 a billable ICD-10 code?
Yes, C86.41 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C86.41?
Clinical documentation must specify the nature of Blastic NK-cell lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference